Dengue Fever Clinical, Companies, Therapy Assessment, Treatment, Pipeline | Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec, Codagenix

DelveInsight's, "Dengue Fever - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dengue Fever Pipeline constitutes 8+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analyzes DelveInsight.

Dengue Fever Overview:

Dengue fever is a mosquito-borne viral illness caused by the dengue virus, transmitted mainly through the bite of infected Aedes aegypti mosquitoes. The disease is widespread in tropical and subtropical regions, particularly across Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America.

It typically begins with a sudden high fever, accompanied by severe headache, pain behind the eyes, joint and muscle pain, skin rash, and mild bleeding symptoms such as nosebleeds, gum bleeding, or easy bruising. These symptoms usually appear 4-10 days after infection and may persist for 2-7 days.

The severity of dengue can range from mild illness to life-threatening complications. Severe dengue-also known as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS)-can cause intense abdominal pain, continuous vomiting, rapid breathing, bleeding gums, extreme fatigue, restlessness, and blood in vomit or stool. If not treated promptly, these symptoms can lead to shock, organ failure, and death. Children and individuals experiencing a second dengue infection are at greater risk of developing severe disease.

Currently, no specific antiviral therapy exists for dengue fever. Treatment is primarily supportive, focusing on hydration, symptom management, and close monitoring. Preventive measures remain the cornerstone of dengue control-these include using mosquito repellents, wearing protective clothing, and eliminating stagnant water to disrupt mosquito breeding.

While vaccination research continues, Dengvaxia is currently the only approved vaccine in select endemic areas. However, it is recommended only for individuals with prior dengue infection, as vaccination in those without prior exposure may increase the risk of severe disease. Public health strategies aimed at mosquito control and community awareness remain vital to preventing and managing dengue outbreaks.

Request for a detailed insights report on Dengue Fever pipeline insights [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Dengue Fever Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Dengue Fever Therapeutics Market.

Key Takeaways from the Dengue Fever Pipeline Report

*
DelveInsight's Dengue Fever pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Dengue Fever treatment.

*
Brazil launched what is described as the world's largest mosquito bio-factory in Curitiba, capable of producing ~100 million mosquito eggs per week, infected with the bacterium Wolbachia pipientis to suppress disease-carrying mosquito populations. This initiative aims to protect ~140 million people from dengue and other mosquito-borne diseases.

*
Key Dengue Fever companies such as Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec, Codagenix, and others are evaluating new drugs for Dengue Fever to improve the treatment landscape.

*
Promising Dengue Fever pipeline therapies in various stages of development include V181, EYU-688, and others.

Dengue Fever Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Dengue Fever Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dengue Fever market.

Download our free sample page report on Dengue Fever pipeline insights [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Dengue Fever Emerging Drugs

*
V181: Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine developed by Merck & Co. to protect against dengue fever, a mosquito-borne viral disease prevalent in tropical and subtropical regions worldwide. The vaccine utilizes purified inactivated virus (PIV) technology, a platform designed to stimulate a robust immune response without causing infection, similar to other inactivated viral vaccines.

Preliminary studies have shown that V181 induces a broad and balanced immune response against all four dengue virus serotypes, with the goal of offering comprehensive protection and reducing the risk of severe manifestations such as dengue hemorrhagic fever. The vaccine is currently in the Phase II stage of clinical development for dengue prevention.

*
EYU-688: Novartis Pharmaceuticals

EYU-688 is an orally administered small-molecule therapy developed by Novartis for the treatment of dengue fever. It acts by targeting nonstructural protein 4B (NS4B) and the somatostatin receptor (SSTR), key components involved in viral replication and host response. The drug is currently in Phase II clinical development for dengue fever.

Dengue Fever Companies

Around eight or more key companies are actively developing therapies for Dengue Fever. Among them, Merck Sharp & Dohme LLC and Novartis Pharmaceuticals have drug candidates in the most advanced stage of development-Phase II clinical trials.

DelveInsight's report covers around 75+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Dengue Fever Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Dengue Fever Therapies and Key Companies: Dengue Fever Clinical Trials and advancements [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Dengue Fever Pipeline Therapeutic Assessment

- Dengue Fever Assessment by Product Type

- Dengue Fever By Stage

- Dengue Fever Assessment by Route of Administration

- Dengue Fever Assessment by Molecule Type

Download Dengue Fever Sample report to know in detail about the Dengue Fever treatment market @ Dengue Fever Therapeutic Assessment [https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Dengue Fever Current Treatment Patterns

4. Dengue Fever - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Dengue Fever Late-Stage Products (Phase-III)

7. Dengue Fever Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dengue Fever Discontinued Products

13. Dengue Fever Product Profiles

14. Dengue Fever Key Companies

15. Dengue Fever Key Products

16. Dormant and Discontinued Products

17. Dengue Fever Unmet Needs

18. Dengue Fever Future Perspectives

19. Dengue Fever Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Dengue Fever Pipeline Reports Offerings [https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dengue-fever-clinical-companies-therapy-assessment-treatment-pipeline-johnson-johnson-novartis-pharmaceuticals-merck-sharp-dohme-llc-panacea-biotec-codagenix]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.